Department of Obstetrics and Gynecology, College of Medicine, University of Al-Qadisiyah, Al Diwaniyah, Iraq.
Department of Pharmacology, College of Medicine, University of Al-Qadisiyah, Al Diwaniyah, Iraq.
J Med Life. 2023 May;16(5):725-730. doi: 10.25122/jml-2023-0069.
Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularities, high androgen levels, and ovarian cysts. Clomiphene citrate (Clomid) and letrozole have both been investigated as ovulation induction therapies for PCOS. This interventional study aimed to compare the efficacy and safety of a stairstep practice of letrozole versus clomiphene citrate in women with PCOS. A total of 100 women diagnosed with PCOS and infertility participated in the study, which took place from March 2021 to July 2022 at the Maternity and Children Teaching Hospital in Adiwaniyah Province, Iraq. Participants were randomly assigned to one of two groups (each with 50 women): the first group received clomiphene citrate in a stair step pattern (single dose of 50 mg, 100 mg, and 150 mg) for five days, for a maximum of three cycles; the second group received letrozole in a stair step pattern (single dose of 2.5, 5, and 7.5 mg) for five days, for a maximum of three cycles. Follicle size was monitored using ultrasound to achieve a follicle size >18 mm. The ovulation rate was higher in the letrozole group (86.0%) compared to the clomiphene citrate group (72.0%), although the difference was not statistically significant (p=0.086). The pregnancy rate was slightly higher in the letrozole group (22.0% 18.0%), but also not statistically significant (p=0.617). However, the mean time from menstruation to ovulation was significantly shorter in the letrozole group (17.20±1.32 days) compared to the clomiphene citrate group (24.08 ± 1.56 days, p<0.001). There were no significant differences in common side effects between the two groups. Overall, letrozole was found to be as safe as clomiphene citrate but demonstrated a shorter time to ovulation. Further studies with larger sample sizes are necessary to validate these findings and determine their clinical implications.
多囊卵巢综合征(PCOS)的特征是月经不规律、雄激素水平高和卵巢囊肿。枸橼酸氯米芬(Clomid)和来曲唑都被研究用于治疗 PCOS 的排卵诱导治疗。这项干预性研究旨在比较来曲唑阶梯式治疗与枸橼酸氯米芬治疗多囊卵巢综合征患者的疗效和安全性。2021 年 3 月至 2022 年 7 月,伊拉克阿迪瓦尼耶省妇产儿童医院对 100 名诊断为 PCOS 和不孕的女性进行了这项研究。参与者被随机分配到两组中的一组(每组 50 名女性):第一组接受枸橼酸氯米芬阶梯式治疗(单次剂量为 50mg、100mg 和 150mg,连续 5 天,最多 3 个周期);第二组接受来曲唑阶梯式治疗(单次剂量为 2.5mg、5mg 和 7.5mg,连续 5 天,最多 3 个周期)。使用超声监测卵泡大小,以达到卵泡大小>18mm。来曲唑组的排卵率(86.0%)高于枸橼酸氯米芬组(72.0%),但差异无统计学意义(p=0.086)。来曲唑组的妊娠率略高(22.0% 比 18.0%),但也无统计学意义(p=0.617)。然而,来曲唑组的平均从月经到排卵的时间明显短于枸橼酸氯米芬组(17.20±1.32 天比 24.08 ± 1.56 天,p<0.001)。两组常见副作用无显著差异。总体而言,来曲唑与枸橼酸氯米芬一样安全,但排卵时间更短。需要更大样本量的进一步研究来验证这些发现并确定其临床意义。